Docteur Laura PINA VEGAS

Thèses universitaires

• Efficacité et tolérance des traitements ciblés du rhumatisme psoriasique : études de cohorte en « vraie vie » à partir des données du Système National des Données de Santé

  Efficacy and safety of targeted therapies for psoriatic arthritis: a cohort study of the French health insurance database

  Santé publique - recherche clinique🎓 Paris 12

  Direction : Émilie Sbidian, Pascal Claudepierre

Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.

Bibliographie

• Preconception, pregnancy and postpartum periods in spondyloarthritis: Unmet needs and challenges from a patients and rheumatologists surveys

  2026

  ArticleJoint Bone Spine

• French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

  2025

  ArticleJournal of the European Academy of Dermatology and Venereology

• Ten-year follow-up of degenerative spinal lesions on radiographs and MRI in axial spondyloarthritis: results of the DESIR (DEvenir des spondylarthropathies indifférenciées récentes) cohort

  2025

  ArticleEuropean Radiology

• Recurrences and rechallenges of suspected drugs in patients with epidermal necrolysis

  2025

  ArticleClinical and Experimental Dermatology

• When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it?

  2025

  ArticleRMD Open : Rheumatic & Musculoskeletal Diseases

• Unmet needs in axial spondyloarthritis. Proceedings of the French spondyloarthritis taskforce workshop

  2024

  ArticleJoint Bone Spine

• Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS)

  2024

  ArticleRMD Open

• Pregnancy outcomes in women with rheumatoid arthritis: an 11-year French nationwide study

  2024

  ArticleRMD Open

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Livres & ouvrages

• 📕

  Caractéristiques épidémiologiques, cliniques, étiologiques et thérapeutiques d'une cohorte de syndrome cochléo-vestibulaires avec hypersignal spontané FLAIR du labyrinthe en IRM

  étude rétrospective monocentrique

  2021 · 104 p.

Source : Google Books — filtre catégories médicales/santé/sciences.

Lieu de consultation

• GHU APHP HM SITE HENRI MONDOR

  51 Avenue MAL DE LATTRE DE TASSIGNY, 94010 Créteil

  ☎ 0149812111Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

  Annals of the rheumatic diseases · 2023

  📚 99 citations🎯 RCR 14.12Top 1% NIH
• 2

  Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis

  JAMA dermatology · 2021

  📚 77 citations🎯 RCR 6.59Top 5% NIH🔓 Open Access📄 PDF gratuit ↗
• 3

  Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database

  JAMA dermatology · 2022

  📚 54 citations🎯 RCR 5.91Top 6% NIH🔓 Open Access

  Lire l'abstract Crossref ↓

  ImportanceTreatment options for psoriasis (PsO) and psoriatic arthritis (PsA) have evolved significantly throughout the era of biologics. Clinical trials are inadequate to assess the relative long-term efficacy of biologics and are often insufficient regarding safety.ObjectivesTo assess the long-term persistence of different biologic classes to treat PsO and PsA.Design, Setting, and ParticipantsThis nationwide cohort study involved the administrative health care database of the French health insurance scheme linked to the hospital discharge database. All adults with PsO and PsA who were new users of biologics (not in the year before the index date) from January 1, 2015, to May 31, 2019, were included and followed up through December 31, 2019. Patients hospitalized for PsA in the PsO cohort and for PsO in the PsA cohort in the year before the index date were excluded. Data were analyzed from June 1 to October 31, 2021.Main Outcomes and MeasuresPersistence was defined as the time from biologic therapy initiation to discontinuation and was estimated using the Kaplan-Meier method. Comparison of persistence by biologic class involved using propensity score–weighted Cox proportional hazards regression models and adjustment on specific systemic nonbiologics (time-dependent variables).ResultsA total of 16 892 patients with PsO were included in the analysis (mean [SD] age, 48.5 [13.8] years; 9152 men [54.2%] men). Of these, 10 199 patients (60.4%) started therapy with a tumor necrosis factor (TNF) inhibitor; 3982 (23.6%), with an interleukin 12 and interleukin 23 (IL-12/23) inhibitor; and 2711 (16.0%), with an interleukin 17 (IL-17) inhibitor. An additional 6531 patients with PsA (mean [SD] age, 49.1 [12.8] years; 3565 [54.6%] women) were included; of these, 4974 (76.2%) started therapy with a TNF inhibitor; 803 (12.3%), with an IL-12/23 inhibitor; and 754 (11.5%), with an IL-17 inhibitor. Overall 3-year persistence rates were 40.9% and 36.2% for PsO and PsA, respectively. After inverse probability of treatment weighting and adjustment, the IL-17 inhibitor was associated with higher persistence compared with the TNF inhibitor for PsO (weighted hazard ratio [HR], 0.78 [95% CI, 0.73-0.83]) and PsA (weighted HR, 0.70 [95% CI, 0.58-0.85]) and compared with the IL-12/23 inhibitor for PsA (weighted HR, 0.69 [95% CI, 0.55-0.87]). No difference between the IL-17 inhibitor and IL-12/23 inhibitor for PsO was noted. The IL-12/23 inhibitor was associated with higher persistence than the TNF inhibitor for PsO (weighted HR, 0.76 [95% CI, 0.72-0.80]), with no difference observed for PsA.Conclusions and RelevanceThe findings of this cohort study suggest that IL-17 inhibitors are associated with higher treatment persistence than the TNF inhibitor for PsO and PsA. Interleukin 17 inhibitors were also associated with higher persistence than the IL-12/23 inhibitor for PsA, with no difference for PsO. However, the persistence rates of all biologics remained globally low at 3 years.

Publications scientifiques (30) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche